Medicale Corp.
MCLEDrugs in Pipeline
24
Phase 3 Programs
8
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Sevre-Long™
Opiate Dependent
Adoptive Cellular Therapy
Cytomegalovirus Infection
Tadalafil 5mg (Male)
Erectile Dysfunction
IVACFLU-A/H5N1 vaccine
Avian Influenza
GDC 268 Lotion
Acne Vulgaris
IVACFLU-S
Influenza, Human
Ibuprofen and Aprepitant
Primary Dysmenorrhea
GDC-229
Bacterial Vaginosis
Oxytocin
Atrophy
FX06
Myocardial Ischemia
EPODURE (dermal Biopump for erythropoietin)
Anemia
COVIVAC vaccine
COVID-19
Glyceryl trinitrate
Erectile Dysfunction
Osteodex
Prostate Cancer Metastatic
low-dose group (naltrexone implant 0.9 g + general supportive psychological counseling)
AUD
ODX (Osteodex)
Multiple Myeloma
1.5g Naltrexone Implant
Opioid Dependence
Tavokinogene Telseplasmid (tavo)
Melanoma
Oxytocin 100 i.u.
Vaginal Atrophy
Oxytocin 400 IU vaginal gel
Vulvovaginal Atrophy
CMV-specific T-cells, single infusion following single positive CMV PCR result
Cytomegalovirus Infection
Cytovir-ADV
ADV Infection Post Allo-HSCT
Nab paclitaxel
Pancreatic Cancer
Oral Tablet: Cabozantinib
Colorectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sevre-Long™ | Phase 3 | Opiate Dependent | - | - |
Adoptive Cellular Therapy | Phase 3 | Cytomegalovirus Infection | - | - |
Tadalafil 5mg (Male) | Phase 3 | Erectile Dysfunction | - | - |
IVACFLU-A/H5N1 vaccine | Phase 3 | Avian Influenza | - | - |
GDC 268 Lotion | Phase 3 | Acne Vulgaris | - | - |
IVACFLU-S | Phase 3 | Influenza, Human | - | - |
Ibuprofen and Aprepitant | Phase 3 | Primary Dysmenorrhea | - | - |
GDC-229 | Phase 3 | Bacterial Vaginosis | - | - |
Oxytocin | Phase 2 | Atrophy | - | - |
FX06 | Phase 2 | Myocardial Ischemia | - | - |
EPODURE (dermal Biopump for erythropoietin) | Phase 2 | Anemia | - | - |
COVIVAC vaccine | Phase 2 | COVID-19 | - | - |
Glyceryl trinitrate | Phase 2 | Erectile Dysfunction | - | - |
Osteodex | Phase 2 | Prostate Cancer Metastatic | - | - |
low-dose group (naltrexone implant 0.9 g + general supportive psychological counseling) | Phase 2 | AUD | - | - |
ODX (Osteodex) | Phase 2 | Multiple Myeloma | - | - |
1.5g Naltrexone Implant | Phase 2 | Opioid Dependence | - | - |
Tavokinogene Telseplasmid (tavo) | Phase 2 | Melanoma | - | - |
Oxytocin 100 i.u. | Phase 2 | Vaginal Atrophy | - | - |
Oxytocin 400 IU vaginal gel | Phase 2 | Vulvovaginal Atrophy | - | - |
CMV-specific T-cells, single infusion following single positive CMV PCR result | Phase 2 | Cytomegalovirus Infection | - | - |
Cytovir-ADV | Phase 2 | ADV Infection Post Allo-HSCT | - | - |
Nab paclitaxel | Phase 2 | Pancreatic Cancer | - | - |
Oral Tablet: Cabozantinib | Phase 2 | Colorectal Cancer | - | - |
Frequently asked questions
What is in Medicale Corp.'s drug pipeline?→
CatalystAlert tracks 24 drug candidates in Medicale Corp.'s (MCLE) pipeline across Phase 3, Phase 2. Its lead program is Sevre-Long™ (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Medicale Corp.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Medicale Corp. (MCLE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MCLE biotech catalysts?→
Add MCLE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Medicale Corp.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.